TY  - JOUR
A1  - Wenzel, Mike
A1  - Nocera, Luigi
A1  - Collà Ruvolo, Claudia
A1  - Würnschimmel, Christoph
A1  - Tian, Zhe
A1  - Shariat, Shahrokh F.
A1  - Saad, Fred
A1  - Tilki, Derya
A1  - Graefen, Markus
A1  - Kluth, Luis
A1  - Briganti, Alberto
A1  - Mandel, Philipp
A1  - Montorsi, Francesco
A1  - Chun, Felix
A1  - Karakiewicz, Pierre I.
T1  - Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
N2  - Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-021-00395-4, published online 30 May 2021
Y1  - 2023
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/75297
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-752977
SN  - 1476-5608
N1  - Korrektur zu: Wenzel, M., Nocera, L., Collà Ruvolo, C. et al. Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis (2023). https://doi.org/10.1038/s41391-023-00656-4
VL  - 26.2023
SP  - 1
EP  - 2
PB  - Stockton Press
CY  - Basingstoke
ER  -